Drug intelligence / Profile preview

fluconazole + meropenem

Development stage: Preclinical
Lead developer: Sumitomo Pharma
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of fluconazole (a triazole antifungal) and meropenem (a carbapenem antibiotic). This combination has been studied for its effectiveness against polymicrobial biofilms, particularly those formed by Pseudomonas aeruginosa and Candida albicans. Research indicates that the combination therapy may be more effective than monotherapy with either drug alone in reducing biofilm formation.

Targets

CYP51A1 (Sterol 14α-demethylase)PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on fluconazole + meropenem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluconazole + meropenem.

Explore the full profile